HD-OPM Archive
Hashtags

#pcsk9reverse

15 posts

Six RCTs show statins reverse total plaque volume by 5% to 17%

Aug 25, 2026 · Louis Nervegna ♥ 27 · 💬 9 ↩ 1 Plaque, CAC & CT angiography

Louis lists six randomized trials showing reversal of total atheroma volume with statins: COSMOS ~5%, SATURN ~5.5%, ASTEROID ~6.5%, IBIS-4 ~7.5%, STABLE ~8%, JAPAN-ACS ~17%. Reversals were measured by CT angiography or IVUS and came from soft rather than calcified plaque. A shared chart relates LDL to TAV change across statin, PCSK9 and ezetimibe trials.

YELLOW trials: intensive rosuvastatin cut lipid-core plaque within 7-8 weeks

Aug 15, 2026 · Louis Nervegna ♥ 16 · 💬 19 Plaque, CAC & CT angiography

The YELLOW study found that short-term intensive lipid lowering with rosuvastatin reduced lipid-core burden (yellow plaque) in coronary lesions in as little as 7-8 weeks, stabilizing vulnerable plaque rather than shrinking blockages. YELLOW III added the PCSK9 inhibitor evolocumab to statins with greater improvement in plaque composition. Generic rosuvastatin costs under $10/month.

About 95% of acute-thrombosis heart attacks involve soft plaque, not calcified plaque

Oct 03, 2026 · Louis Nervegna ♥ 9 · 💬 9 Plaque, CAC & CT angiography

The post says about 64% of heart attacks from acute thrombosis come from rupture of soft lipid-rich plaque and about 25% from erosion of soft plaque, while only about 5% involve calcified nodules. Because statins and other lipid-lowering drugs stabilize and reverse soft plaque, the poster argues they address the plaque type most responsible for heart attacks.

Keto-CTA plaque progression vs plaque regression on Repatha in Budoff's other study

Apr 09, 2025 · Louis Nervegna ♥ 8 · 💬 2 Plaque, CAC & CT angiography

Louis compares non-calcified plaque volume (NCPV) changes in the Keto-CTA (LMHR) study with a second Matthew Budoff study in higher-risk people whose LDL was lowered to about 30 mg/dL with the PCSK9 inhibitor Repatha. The lean, healthy keto group with LDL 254 mg/dL progressed, while the hypertensive, higher-risk Repatha group mostly showed major regression. He also notes that uL and mm^3 are the same unit when comparing NCPV across studies.

Repatha alone reversed soft plaque in 37 of 47 patients over 18 months at LDL near 30

Nov 13, 2026 · Louis Nervegna ♥ 9 · 💬 1 PCSK9, ezetimibe & newer drugs

Louis explains a small uncontrolled study of the PCSK9 inhibitor evolocumab with CT angiography. Average LDL was about 30 mg/dL, 37 of 47 patients had some non-calcified plaque regression, and many had large reversals worth years of typical growth (about 5 mm3 per year). He cautions it was small with no randomization or control group, and that PCSK9 monotherapy is not yet proven to reduce heart attacks.

Six statin trials show 5 to 17% total plaque reversal, with the best results at lowest LDL

Oct 31, 2026 · Louis Nervegna ♥ 12 ↩ 1 Plaque, CAC & CT angiography

Louis shares a chart of randomized trials showing plaque reversal with statins, ezetimibe and PCSK9 inhibitors, with total atheroma volume change plotted against LDL-C. Total plaque reversal ranged from about 5% to 17% in six older statin trials, measured by CT angiography or IVUS, and came from soft rather than calcified plaque. The chart suggests total plaque reversal begins once LDL falls below roughly 90 mg/dL.